多西紫杉醇
医学
前列腺癌
肿瘤科
化疗
内科学
雄激素剥夺疗法
前列腺
癌症
作者
Robert E. Miller,Christopher J. Sweeney
摘要
The role of docetaxel chemotherapy in combination with androgen deprivation therapy for metastatic castrate-sensitive prostate cancer is emerging.We reviewed the results from the pivotal randomized phase III trials in this area: GETUG15, CHAARTED and STAMPEDE.All three studies demonstrated a benefit in progression-free survival with the use of docetaxel. However, two of the studies demonstrated a clinically meaningful overall survival benefit (CHAARTED and STAMPEDE), whereas the GETUG15 study did not demonstrate a major benefit.Docetaxel is an important option to consider for men who are fit for chemotherapy with newly diagnosed metastatic prostate cancer commencing androgen deprivation therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI